Digital Whole Slide Image Analysis of Elevated Stromal Content and Extracellular Matrix Protein Expression Predicts Adverse Prognosis in Triple-Negative Breast Cancer
-
Published:2024-08-30
Issue:17
Volume:25
Page:9445
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Karancsi Zsófia1, Gregus Barbara1, Krenács Tibor2ORCID, Cserni Gábor34, Nagy Ágnes2, Szőcs-Trinfa Klementina Fruzsina1, Kulka Janina1ORCID, Tőkés Anna Mária1
Affiliation:
1. Department of Pathology Forensic and Insurance Medicine, Semmelweis University, 1091 Budapest, Hungary 2. Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary 3. Department of Pathology, Albert Szent-Györgyi Faculty of Medicine, University of Szeged, 6725 Szeged, Hungary 4. Department of Pathology, Bács-Kiskun County Teaching Hospital, 6000 Kecskemét, Hungary
Abstract
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis and limited treatment options. This study evaluates the prognostic value of stromal markers in TNBC, focusing on the tumor–stroma ratio (TSR) and overall stroma ratio (OSR) in whole slide images (WSI), as well as the expression of type-I collagen, type-III collagen, and fibrillin-1 on tissue microarrays (TMAs), using both visual assessment and digital image analysis (DIA). A total of 101 female TNBC patients, primarily treated with surgery between 2005 and 2016, were included. We found that high visual OSR correlates with worse overall survival (OS), advanced pN categories, lower stromal tumor-infiltrating lymphocyte count (sTIL), lower mitotic index, and patient age (p < 0.05). TSR showed significant connections to the pN category and mitotic index (p < 0.01). High expression levels of type-I collagen (>45%), type-III collagen (>30%), and fibrillin-1 (>20%) were linked to significantly worse OS (p = 0.004, p = 0.013, and p = 0.005, respectively) and progression-free survival (PFS) (p = 0.028, p = 0.025, and p = 0.002, respectively), validated at the mRNA level. Our results highlight the importance of stromal characteristics in promoting tumor progression and metastasis and that targeting extracellular matrix (ECM) components may offer novel therapeutic strategies. Furthermore, DIA can be more accurate and objective in evaluating TSR, OSR, and immunodetected stromal markers than traditional visual examination.
Reference54 articles.
1. Lukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanislawek, A. (2021). Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers, 13. 2. Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2018). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https://gco.iarc.who.int/today. 3. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013;Goldhirsch;Ann. Oncol.,2013 4. Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape;Mehanna;Int. J. Womens Health,2019 5. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage;Mesker;Cell. Oncol.,2007
|
|